Ardelyx (NASDAQ:ARDX) Insider John Bishop Sells 19,750 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX) insider John Bishop sold 19,750 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $76,235.00. Following the sale, the insider owned 317,095 shares in the company, valued at approximately $1,223,986.70. This trade represents a 5.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Ardelyx Stock Up 1.1%

Shares of Ardelyx stock opened at $3.78 on Wednesday. The company has a debt-to-equity ratio of 1.69, a current ratio of 3.34 and a quick ratio of 3.15. The company has a 50-day moving average of $4.97 and a 200 day moving average of $5.75. The firm has a market cap of $941.94 million, a price-to-earnings ratio of -17.18 and a beta of 0.70. Ardelyx, Inc. has a 1 year low of $3.72 and a 1 year high of $8.40.

Ardelyx (NASDAQ:ARDX) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.02). Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. The business had revenue of $120.88 million for the quarter, compared to analysts’ expectations of $121.03 million. During the same period last year, the business earned ($0.08) earnings per share. The company’s revenue was up 34.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Ardelyx, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Wedbush reissued an “outperform” rating and issued a $9.00 price target on shares of Ardelyx in a research report on Tuesday, August 18th. Citigroup lowered their price objective on Ardelyx from $14.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Zacks Research downgraded Ardelyx from a “hold” rating to a “strong sell” rating in a report on Wednesday, July 22nd. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Ardelyx in a research note on Friday, August 7th. Finally, Piper Sandler reduced their price target on Ardelyx from $16.00 to $15.00 and set an “overweight” rating for the company in a report on Monday, August 17th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.90.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Despite the negative signals below, the stock has increased modestly, suggesting buyers have so far absorbed the recent selling pressure.
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio, while also describing the change as a “large increase.” Because the figures are internally inconsistent, they provide no reliable signal for ARDX.
• Negative Sentiment: Eight Ardelyx insiders sold a combined 126,059 shares for approximately $486,588 at an average price of $3.86 on August 21. The sales included CEO Michael Raab, who sold 58,574 shares, and CFO Susan Hohenleitner, who sold 1,558 shares. The transactions reduced each insider’s holdings, though all retained substantial positions. CEO insider sale filing
• Negative Sentiment: Options traders purchased 11,731 put contracts on Tuesday, roughly 328% above the average volume of 2,743 contracts. The surge indicates increased hedging or bearish speculation around Ardelyx, although options activity alone does not confirm a fundamental deterioration.

Institutional Investors Weigh In On Ardelyx

Several institutional investors and hedge funds have recently made changes to their positions in ARDX. Northwestern Mutual Wealth Management Co. bought a new position in Ardelyx in the 2nd quarter valued at approximately $35,000. SCS Capital Management LLC bought a new stake in shares of Ardelyx in the 2nd quarter worth $52,000. ADAR1 Capital Management LLC purchased a new position in shares of Ardelyx in the second quarter worth $56,000. Krilogy Financial LLC purchased a new position in shares of Ardelyx in the first quarter worth $70,000. Finally, PVG Asset Management Corp bought a new position in shares of Ardelyx during the first quarter valued at $65,000. Institutional investors own 58.92% of the company’s stock.

About Ardelyx

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.